tirzepatide and glp 1 the same Associated with Lower POAG, OHT Risk Compared with Other GLP-1 Drugs Retatrutide vs Tirzepatide vs Semaglutide

The results between analysed groups were compared using the Students t -test

Please do not ask questions that use sensitive or confidential information

Type 2 diabetes mellitus (DM2) affects a 13.8% of the Spanish population1 and its prevalence is expected to increase in the future.2 The presence of DM2 increases significantly the risk of cardiovascular events, chronic kidney disease (CKD), and premature death3,4 and as its prevalence increases it is expected to rise the incidence of microvascular and macrovascular complications.5 Until the last decade, the control of blood glucose, blood pressure, dyslipidemia, and the use of inhibitors of the renin-angiotensin system (iSRA) have been the only strategies available to reduce cardiovascular and renal risk in this population

GLP-1 medications can improve sleep quality and reduce sleep apnea symptoms through weight loss and direct effects on sleep patterns